IC
FLGT icon

Innealta Capital’s Fulgent Genetics FLGT Stock Holding History

Innealta Capital’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24
Closed -$471 – 712
2024
Q2 		$471 Buy
+24
New +$501 ﹤0.01% 1480

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Innealta Capital's FLGT Position: Q3 2024 in Review

Innealta Capital sold out of Fulgent Genetics (FLGT) in Q3 2024, closing a stake of 24 shares — an estimated $471 sold.

Innealta Capital first reported a position in FLGT in Q2 2024 and held it in 1 quarter. The position peaked at $471 in Q2 2024. 183 funds tracked by Wall St. Rank hold FLGT as of Q3 2024.

  • Innealta Capital reported no remaining Fulgent Genetics position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 24 Fulgent Genetics shares in Q3 2024, an estimated $471.
  • Innealta Capital first reported a position in Fulgent Genetics in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Fulgent Genetics position peaked at $471 in Q2 2024.
  • 183 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.